Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

QIAGEN Launches QuantiFERON-TB Gold In-Tube in China

Published: Thursday, March 20, 2014
Last Updated: Thursday, March 20, 2014
Bookmark and Share
Pioneering blood test that accurately identifies people infected with Mycobacterium tuberculosis, the bacterium that causes tuberculosis.

QuantiFERON-TB has become the test of choice around the world and is displacing the century-old tuberculin skin test (TST) in screening for TB infection. QIAGEN already sells QuantiFERON-TB in many markets, including the U.S. and Europe, and gained approval earlier this year from the China Food and Drug Administration (CFDA). QIAGEN announced the QuantiFERON-TB launch to coincide with World TB Day 2014, Monday March 24.

China has an estimated 1 million reported new cases of active TB each year, more than any country except India, according to the World Health Organization (WHO). Based on the previous survey, an estimated 550 million people in China, 41% of the population, are infected with the TB bacterium. Globally, WHO estimates one-third of the world’s population has latent TB infection. Left untreated 5 to 10% of these people will develop active disease during their lifetimes, often when they experience weakened immunity due to other health issues. With the accelerating urbanization in China, the large population with latent TB infection will potentially increase the incidence of TB disease and transmission of the infection. The incidence of multidrug-resistant TB (MDR-TB) and extreme drug resistance TB (XDR-TB), as well as increased co-morbidities such as human immunodeficiency virus (HIV), diabetes and rheumatoid arthritis, make TB control more challenging. In 2012, WHO recommended that an interferon-gamma (IFN-g) release assay (IGRA) could be part of clinical evaluation for investigating contacts of persons with infectious tuberculosis in low-and middle-income countries.

QIAGEN’s QuantiFERON-TB is the industry-leading IGRA, a modern breakthrough blood test that is faster, more accurate and cost-effective than older methods. QuantiFERON-TB, which measures the body’s cell-mediated immune response to a cocktail of TB-specific antigens, is one of the most studied IGRA and commonly used TB-screening assay in industry and clinical research. Compared with the tuberculin skin test (TST or Mantoux), QuantiFERON-TB is a more precise, easier-to-handle modern alternative. It can reduce false-positive readings caused by the Bacille Calmette-Guérin (BCG) vaccination, which all newborns in countries like China receive as a matter of policy. The TST is notoriously inaccurate in BCG-vaccinated persons because of cross-reacting antigens that commonly cause false positive results.

“We are pleased to announce the launch of QuantiFERON-TB in China, where QIAGEN has a major presence, to support TB control efforts. Use of QuantiFERON-TB to screen vulnerable populations is growing rapidly in the United States, Europe and other markets, and we are focusing on this important product as one of QIAGEN’s global growth drivers,” said Peer Schatz, QIAGEN’s Chief Executive Officer. “The superiority of QIAGEN’s QuantiFERON technology to deliver more reliable results than the 120-year-old tuberculin skin test already is well accepted among physicians in China, paving the way for the entry of QuantiFERON-TB into this important market.”

QIAGEN advocates for the ethical usage of QuantiFERON-TB and will target its screening efforts to vulnerable subpopulations including immuno-compromised patients such as those with HIV or diabetes, as well as people with weaker immune systems such as children, the elderly, malnourished, heavy smokers and drug abusers, who have a much higher chance of progressing from latent infection to active TB. In addition, healthcare workers and groups living in congregate settings are more likely to get active TB and pass it on afterwards.

QIAGEN is committed to working with experts to encourage research and raise awareness of the disease. Around World TB Day 2014, the company has participated in activities worldwide, including Germany, France, the UK, North America, Philippines, Malaysia, Pakistan and other countries to support the research and development of TB control.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Food Triggers Creation of Regulatory T Cells
IBS researchers document how normal diet establishes immune tolerance conditions in the small intestine.
Therapeutic Approach Gives Hope for Multiple Myeloma
A new therapeutic approach tested by a team from Maisonneuve-Rosemont Hospital (CIUSSS-EST, Montreal) and the University of Montreal gives promising results for the treatment of multiple myeloma, a cancer of the bone marrow currently considered incurable with conventional chemotherapy and for which the average life expectancy is about 6 or 7 years.
Cellular 'Relief Valve'
A team led by scientists at The Scripps Research Institute (TSRI) has solved a long-standing mystery in cell biology by showing essentially how a key “relief-valve” in cells does its job.
Switch Lets Salmonella Fight, Evade Immune System
Researchers at the University of Illinois at Chicago have discovered a molecular regulator that allows salmonella bacteria to switch from actively causing disease to lurking in a chronic but asymptomatic state called a biofilm.
Tricked-Out Immune Cells Could Attack Cancer
New cell-engineering technique may lead to precision immunotherapies.
Neural Networks Adapt to the Presence of a Toxic HIV Protein
HIV-associated neurocognitive disorders (HAND) afflict approximately half of HIV infected patients.
HIV Protein Manipulates Hundreds of Human Genes
Findings search for new or improved treatments for patients with AIDS.
Breaking the Brain’s Garbage Disposal
The children’s ataxia gene problem turned out to be not such a big deal genetically — it was such a slight mutation that it barely changed the way the cells made the protein.
Flesh-Eating Bacteria Work Together
Scientists recently discovered different strains of deadly flesh-eating bacteria working together to spread infection and they now have a better understanding of the role of the toxins they produce. The discovery could change how the illness and other diseases are treated.
Utilizing Antibodies from Ebola Survivors
A collaborative team from The University of Texas Medical Branch at Galveston, Vanderbilt University, The Scripps Research Institute and Integral Molecular Inc. have learned that antibodies in the blood of people who have survived a strain of the Ebola virus can kill various types of Ebola.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!